Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors

R. E. Jimenez, M. Hussain, Jr Bianco F.J., U. Vaishampayan, P. Tabazcka, W. A. Sakr, J. E. Pontes, Jr Wood D.P., David Grignon

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Purpose: The prognostic significance of Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder is largely unknown. Accurate determination of Her-2/neu overexpression may have therapeutic importance. Experimental Design: Eighty consecutive cases of muscle-invasive urothelial carcinoma of the bladder treated by radical cystectomy with available follow-up were analyzed. In each case, one representative section was stained with anti-Her-2/neu. Staining was graded as 1 = faint/equivocal, 2 = moderate, and 3 = strong and was considered positive if ≥2. In those cases with a metastasis, the stain was also performed in the metastatic tumor. Results were correlated with survival. Results: Twenty-two (28%) cases were considered Her-2/neu-positive in the primary tumor, and 17 of 32 (53%) were considered Her-2/neu-positive in the lymph node metastasis. Median survival for Her-2/neu-positive primary tumors was 33 months, compared with 50 months for Her-2/neu-negative cases (P = 0.46). Similarly, Her-2/neu overexpression in the lymph node metastasis did not predict survival. Sixty metastatic urothelial carcinomas were further studied by comparing Her-2/neu expression in the primary tumor with that of the lymph node and/or distant metastasis. Forty-five % of Her-2/neu-negative primary tumors had a Her-2/neu-positive lymph node metastasis, whereas only one case (8%) of Her-2/neu-positive primary tumors was Her-2/neu-negative in the lymph node metastasis (P = 0.009). Similarly, 67% of Her-2/neu-negative primary tumors had a Her-2/neu-positive distant metastasis, whereas no Her-2/neu-positive primary tumor was negative in the metastasis (P = 0.429). Conclusions: Her-2/neu overexpression in primary or metastatic tumor did not predict survival in this cohort of muscle-invasive tumors. Overexpression in the primary tumors consistently predicts overexpression in a distant or regional metastasis. However, some Her-2/neu-negative primary tumors may show overexpression in their corresponding metastasis. Her-2/neu analysis in a metastasis may be necessary to accurately determine Her-2/neu status in metastatic bladder urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)2440-2447
Number of pages8
JournalClinical Cancer Research
Volume7
Issue number8
StatePublished - 2001
Externally publishedYes

Fingerprint

Urinary Bladder
Carcinoma
Muscles
Neoplasm Metastasis
Neoplasms
Lymph Nodes
Cystectomy
Research Design
Coloring Agents
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder : Prognostic significance and comparative analysis in primary and metastatic tumors. / Jimenez, R. E.; Hussain, M.; Bianco F.J., Jr; Vaishampayan, U.; Tabazcka, P.; Sakr, W. A.; Pontes, J. E.; Wood D.P., Jr; Grignon, David.

In: Clinical Cancer Research, Vol. 7, No. 8, 2001, p. 2440-2447.

Research output: Contribution to journalArticle

Jimenez, RE, Hussain, M, Bianco F.J., J, Vaishampayan, U, Tabazcka, P, Sakr, WA, Pontes, JE, Wood D.P., J & Grignon, D 2001, 'Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors', Clinical Cancer Research, vol. 7, no. 8, pp. 2440-2447.
Jimenez, R. E. ; Hussain, M. ; Bianco F.J., Jr ; Vaishampayan, U. ; Tabazcka, P. ; Sakr, W. A. ; Pontes, J. E. ; Wood D.P., Jr ; Grignon, David. / Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder : Prognostic significance and comparative analysis in primary and metastatic tumors. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 8. pp. 2440-2447.
@article{2b653c01bf80471ba1af348bedb4a3ba,
title = "Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors",
abstract = "Purpose: The prognostic significance of Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder is largely unknown. Accurate determination of Her-2/neu overexpression may have therapeutic importance. Experimental Design: Eighty consecutive cases of muscle-invasive urothelial carcinoma of the bladder treated by radical cystectomy with available follow-up were analyzed. In each case, one representative section was stained with anti-Her-2/neu. Staining was graded as 1 = faint/equivocal, 2 = moderate, and 3 = strong and was considered positive if ≥2. In those cases with a metastasis, the stain was also performed in the metastatic tumor. Results were correlated with survival. Results: Twenty-two (28{\%}) cases were considered Her-2/neu-positive in the primary tumor, and 17 of 32 (53{\%}) were considered Her-2/neu-positive in the lymph node metastasis. Median survival for Her-2/neu-positive primary tumors was 33 months, compared with 50 months for Her-2/neu-negative cases (P = 0.46). Similarly, Her-2/neu overexpression in the lymph node metastasis did not predict survival. Sixty metastatic urothelial carcinomas were further studied by comparing Her-2/neu expression in the primary tumor with that of the lymph node and/or distant metastasis. Forty-five {\%} of Her-2/neu-negative primary tumors had a Her-2/neu-positive lymph node metastasis, whereas only one case (8{\%}) of Her-2/neu-positive primary tumors was Her-2/neu-negative in the lymph node metastasis (P = 0.009). Similarly, 67{\%} of Her-2/neu-negative primary tumors had a Her-2/neu-positive distant metastasis, whereas no Her-2/neu-positive primary tumor was negative in the metastasis (P = 0.429). Conclusions: Her-2/neu overexpression in primary or metastatic tumor did not predict survival in this cohort of muscle-invasive tumors. Overexpression in the primary tumors consistently predicts overexpression in a distant or regional metastasis. However, some Her-2/neu-negative primary tumors may show overexpression in their corresponding metastasis. Her-2/neu analysis in a metastasis may be necessary to accurately determine Her-2/neu status in metastatic bladder urothelial carcinoma.",
author = "Jimenez, {R. E.} and M. Hussain and {Bianco F.J.}, Jr and U. Vaishampayan and P. Tabazcka and Sakr, {W. A.} and Pontes, {J. E.} and {Wood D.P.}, Jr and David Grignon",
year = "2001",
language = "English (US)",
volume = "7",
pages = "2440--2447",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder

T2 - Prognostic significance and comparative analysis in primary and metastatic tumors

AU - Jimenez, R. E.

AU - Hussain, M.

AU - Bianco F.J., Jr

AU - Vaishampayan, U.

AU - Tabazcka, P.

AU - Sakr, W. A.

AU - Pontes, J. E.

AU - Wood D.P., Jr

AU - Grignon, David

PY - 2001

Y1 - 2001

N2 - Purpose: The prognostic significance of Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder is largely unknown. Accurate determination of Her-2/neu overexpression may have therapeutic importance. Experimental Design: Eighty consecutive cases of muscle-invasive urothelial carcinoma of the bladder treated by radical cystectomy with available follow-up were analyzed. In each case, one representative section was stained with anti-Her-2/neu. Staining was graded as 1 = faint/equivocal, 2 = moderate, and 3 = strong and was considered positive if ≥2. In those cases with a metastasis, the stain was also performed in the metastatic tumor. Results were correlated with survival. Results: Twenty-two (28%) cases were considered Her-2/neu-positive in the primary tumor, and 17 of 32 (53%) were considered Her-2/neu-positive in the lymph node metastasis. Median survival for Her-2/neu-positive primary tumors was 33 months, compared with 50 months for Her-2/neu-negative cases (P = 0.46). Similarly, Her-2/neu overexpression in the lymph node metastasis did not predict survival. Sixty metastatic urothelial carcinomas were further studied by comparing Her-2/neu expression in the primary tumor with that of the lymph node and/or distant metastasis. Forty-five % of Her-2/neu-negative primary tumors had a Her-2/neu-positive lymph node metastasis, whereas only one case (8%) of Her-2/neu-positive primary tumors was Her-2/neu-negative in the lymph node metastasis (P = 0.009). Similarly, 67% of Her-2/neu-negative primary tumors had a Her-2/neu-positive distant metastasis, whereas no Her-2/neu-positive primary tumor was negative in the metastasis (P = 0.429). Conclusions: Her-2/neu overexpression in primary or metastatic tumor did not predict survival in this cohort of muscle-invasive tumors. Overexpression in the primary tumors consistently predicts overexpression in a distant or regional metastasis. However, some Her-2/neu-negative primary tumors may show overexpression in their corresponding metastasis. Her-2/neu analysis in a metastasis may be necessary to accurately determine Her-2/neu status in metastatic bladder urothelial carcinoma.

AB - Purpose: The prognostic significance of Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder is largely unknown. Accurate determination of Her-2/neu overexpression may have therapeutic importance. Experimental Design: Eighty consecutive cases of muscle-invasive urothelial carcinoma of the bladder treated by radical cystectomy with available follow-up were analyzed. In each case, one representative section was stained with anti-Her-2/neu. Staining was graded as 1 = faint/equivocal, 2 = moderate, and 3 = strong and was considered positive if ≥2. In those cases with a metastasis, the stain was also performed in the metastatic tumor. Results were correlated with survival. Results: Twenty-two (28%) cases were considered Her-2/neu-positive in the primary tumor, and 17 of 32 (53%) were considered Her-2/neu-positive in the lymph node metastasis. Median survival for Her-2/neu-positive primary tumors was 33 months, compared with 50 months for Her-2/neu-negative cases (P = 0.46). Similarly, Her-2/neu overexpression in the lymph node metastasis did not predict survival. Sixty metastatic urothelial carcinomas were further studied by comparing Her-2/neu expression in the primary tumor with that of the lymph node and/or distant metastasis. Forty-five % of Her-2/neu-negative primary tumors had a Her-2/neu-positive lymph node metastasis, whereas only one case (8%) of Her-2/neu-positive primary tumors was Her-2/neu-negative in the lymph node metastasis (P = 0.009). Similarly, 67% of Her-2/neu-negative primary tumors had a Her-2/neu-positive distant metastasis, whereas no Her-2/neu-positive primary tumor was negative in the metastasis (P = 0.429). Conclusions: Her-2/neu overexpression in primary or metastatic tumor did not predict survival in this cohort of muscle-invasive tumors. Overexpression in the primary tumors consistently predicts overexpression in a distant or regional metastasis. However, some Her-2/neu-negative primary tumors may show overexpression in their corresponding metastasis. Her-2/neu analysis in a metastasis may be necessary to accurately determine Her-2/neu status in metastatic bladder urothelial carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0034890387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034890387&partnerID=8YFLogxK

M3 - Article

C2 - 11489824

AN - SCOPUS:0034890387

VL - 7

SP - 2440

EP - 2447

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -